Objective: The purpose of this study was to systematically analyze the associations between different TSC1 and TSC2 mutations and the neurologic and cognitive phenotype in patients with tuberous sclerosis complex (TSC).
Results:
As a group, patients with a TSC2 mutation had earlier age at seizure onset, lower cognition index, more tubers, and a greater TBP than those with a TSC1 mutation, but the ranges overlapped considerably. Familial cases were older at seizure onset and had a higher cognition index than nonfamilial cases. Patients with a mutation deleting or directly inactivating the tuberin GTPase activating protein (GAP) domain had more tubers and a greater TBP than those with an intact GAP domain. Patients with a truncating TSC1 or TSC2 mutation differed from those with nontruncating mutations in seizure types only.
Conclusions:
Although patients with a TSC1 mutation are more likely to have a less severe neurologic and cognitive phenotype than those with a TSC2 mutation, the considerable overlap between both aspects of the phenotype implies that prediction of the neurologic and cognitive phenotypes in individuals with tuberous sclerosis complex should not be based on their particular TSC1 or TSC2 mutation. Neurology ® 2008;70:908-915 GLOSSARY GAP ‫؍‬ GTPase activating protein; IE ϭ intelligence equivalent; IS ϭ infantile spasms; mTOR ϭ mammalian target of rapamycin; sGTCS ϭ secondary generalized tonic clonic seizure; TBP ϭ tuber/brain proportion; TSC ϭ tuberous sclerosis complex.
Tuberous sclerosis complex (TSC) is an autosomal dominant disorder characterized by the widespread development of hamartomas in a variety of tissues and organs. TSC is noted for its clinical variability, and there is no single clinical or radiographic sign that is absolutely specific for the disease. A definite clinical diagnosis requires the presence of two major features or one major plus two minor features. 1 Neurologic and neuropsychological manifestations include epilepsy, focal neurologic deficits, mental retardation, and behavioral disturbances. Epilepsy is the most common neurologic symptom in TSC, occurring in 80 to 90% of cases. 2 TSC is caused by a mutation in either the TSC1 gene, with the locus on chromosome 9q34, or the TSC2 gene located on chromosome 16p13. In two-thirds of the TSC popula-tion, the family history of TSC is negative. In the majority of these patients de novo TSC1 or TSC2 mutations are identified. 3 Seventy percent of the de novo mutations are found in the TSC2 gene. In familial cases, about 50% are associated with a TSC1 mutation and about 50% with a TSC2 mutation.
The protein product of TSC1 is called hamartin, that of TSC2 tuberin. 4, 5 Together, hamartin and tuberin form a GTPase activating protein (GAP) complex that inhibits rheb, the GTPase that activates the mammalian target of rapamycin (mTOR). 6, 7 The mTOR pathway regulates a number of important cellular processes including growth, nutrient uptake, and protein translation. 8 Mutations to either TSC1 or TSC2 disrupt the function of the complex, explaining why mutations to either gene cause the same disease. It has been suggested that a more severe phenotype is to be expected in TSC patients with mutations inactivating the tuberin GAP domain. 9 Several independent studies of large cohorts of TSC patients have demonstrated that patients with a TSC2 mutation are more often mentally retarded than patients with a TSC1 mutation. 3, [10] [11] [12] In most of these studies, cognitive ability was estimated clinically or through indirect methods such as level of schooling, 13 rather than with standardized measures, such as intelligence scales.
In the current study, epilepsy, cognitive functioning and tuber load were compared between patients with a TSC1 or a TSC2 mutation, between familial and sporadic cases, between patients with a mutation inactivating the tuberin GAP domain (GAPϪ) and patients with an intact GAP domain (GAPϩ), and between patients with a truncating or nontruncating mutation.
METHODS

Patients. Patients clinically diagnosed with
TSC
1 in the outpatient pediatric neurology, neurology, and internal medicine departments of the University Medical Centre Utrecht, the Netherlands, between 1998 and 2005, in whom mutation analysis of the TSC1 and TSC2 genes had been performed, were included in the study. The sample largely overlaps with that described in the companion study.
14 Nine patients who had not been subjected to MRI scans were included in the present study, but not in the companion study.
Informed consent was obtained from each patient or parent(s).
Mutation analysis. Mutation analysis of the TSC1 and
TSC2 genes was carried out at the Department of Clinical Genetics, Erasmus Medical Centre, Rotterdam, the Netherlands. DNA was extracted from peripheral blood using standard techniques. Mutation analysis was performed on all TSC1 and TSC2 exons and exon boundaries with a combination of single-strand conformational polymorphism analysis, denaturing gradient gel electrophoresis, and direct sequencing. 3 To detect large DNA rearrangements, Southern blotting, fluorescence in situ hybridization, or multiplex ligation-dependent probe amplification was performed. If possible, the parents of the proband were tested to determine whether they carried the mutation detected in the proband. Uncertainty about the pathogenicity of specific TSC1 or TSC2 variants was resolved by assaying the biologic activity of the corresponding tuberin or hamartin variant, as described previously. 15 To investigate whether different mutations, on either gene, were associated with specific neurologic and cognitive phenotypes, the patients were grouped according to mutation type. In addition to comparing individuals with a TSC1 or TSC2 mutation, patients were grouped according to whether the tuberin GAP domain was inactivated (GAPϪ) or still intact (GAPϩ). The GAPϩ group included all TSC1 mutations as well as TSC2 missense mutations outside the GAP domain. Next, patients were grouped into those with truncating mutations (including splice site mutations and large rearrangements) and those with nontruncating mutations (missense or small in-frame insertions and deletions).
Classification of the epilepsy syndrome. Each patient was examined in the outpatient department. Details on seizure history, including age at seizure onset, history of infantile spasms (IS), seizure semiology, and the variety of antiepileptic drugs taken during the course of the disease, were obtained via the history obtained from the patients or their parents and extracted from medical records and previous correspondence. Seizure semiology was classified on the basis of the definitions proposed by the Commission on Classification and Terminology of the International League Against Epilepsy. 16 Seizure types (including a history of IS) were scored as present or absent. EEGs were performed with electrode positions according to the 10-20 system and epileptiform activity was scored as focal or multifocal.
Neuropsychological assessment. Patients participated in a comprehensive cognitive assessment, as elaborated in the companion paper.
14 Every patient underwent at least one of the available intelligence or developmental tests, selected in conformity with the mandate of best clinical practice; the resulting standard scores (IQ and developmental index) were called intelligence equivalent (IE). Depending on the widely varying ages and abilities of the patients, additional tests were selected from a fixed battery covering the major domains of cognition. Administration and scoring were according to the test manuals. The test results were either quotients, centiles, or standard scores. These were converted to a general scale with the values 1 (extremely below aver-age), 2 (below average), 3 (average), or 4 (above average). In tests with cut-off scores, scale values 1 and 3 were used. We assigned a "cognition index" to each patient by adding her/ his scale values and dividing the sum by her/his number of tests. The cognition index could vary between 1.00 and 4.00. This index was used as the cognitive marker and relations between both the cognition index and the IE and different mutation types were analyzed.
Structural brain imaging. MRI was performed on a Phil-
ips Gyroscan ACS-NT 1.5 T whole body system (Philips Medical Systems, Best, the Netherlands). All patients underwent a transaxial or coronal fluid-attenuated inversion recovery scan as described in the companion study.
14 Tuber load was expressed as the number of tubers and the proportion of total brain volume occupied by tubers (excluding CSF) (tuber/brain proportion [TBP]).
Statistical analysis.
We calculated risk ratios with corresponding 95% CI of dichotomized predictive variables (genotype) on dichotomized dependent variables (e.g., epilepsy). Analyses with continuous dependent variables (e.g., cognition index, TBP, and number of tubers) were performed with unpaired t tests yielding mean differences with corresponding 95% CI. Differences in age at seizure onset (determined for patients with epilepsy) were assessed by calculating hazard ratios with corresponding 95% CI with Cox's proportional hazard model (survival analysis). We considered associations significant for p values Յ 0.05; p values Յ 0.1 and Ͼ 0.05 were considered trends.
RESULTS Total sample. Fifty-eight patients, 31 women and 27 men, were included in the study. As shown in figure 1, most patients were subjected to both radiologic and cognitive investigations. Mean age at examination was 20.6 years (range 1.6 to 57 years).
Fifty-two patients (90%) had epilepsy, with age at onset between 1 day and 19 years (median 8 months, mean 2 years). Eighteen patients had a history of IS.
The mean cognition index was 1.8 (range 1.0 to 3.7; 48% of patients had a cognition index severely below average).
The number of tubers ranged from 7 to 58 (mean 28). The mean TBP was 1.3% (range 0.2 to 5.1%). The relationships between tuber load, epilepsy variables, and cognition index are presented in a companion paper.
14 Mutation analysis. Mutation analysis was performed in 53 probands. A pathogenic mutation was identified in 48 (91%; in line with previous studies). 7, [9] [10] [11] In four patients, multiple affected members of a family segregating TSC were investigated. In one case, twins with the same de novo mutation were investigated.
In the majority of patients identification of the pathogenic mutation was straightforward. In two cases (TSC2 2765T¡G [L916R] and TSC1 892T¡G [M224R]), the pathogenic nature of the amino acid substitution was confirmed by functional analysis of the tuberin and hamartin variant isoforms (figures e-1 and e-2 on the Neurology ® Web site; www.neurology.org). In one patient, a TSC2 1253A¡T nucleotide change was identified that co-segregated with TSC in a family. The predicted E412V amino acid substitution did not affect tuberin activity in multiple assays of tuberinhamartin function. However, reverse transcriptase PCR analysis revealed that the A¡T transversion affected the splicing of the TSC2 mRNA and therefore the TSC2 1253A¡T variant was classified as a pathogenic splice site mutation.
A TSC1 mutation was found in 17 probands (32%), including 5 confirmed de novo cases and 10 confirmed familial cases. A TSC2 mutation was found in 31 probands (58%), including 13 confirmed de novo cases and 2 confirmed familial cases. In 23 patients, mutation analysis of the parents of the proband was not performed.
Mutations inactivating the tuberin GAP domain were present in 26 probands, mutations leaving an intact GAP domain were present in 22 probands. Truncating mutations, splice site mutations and large rearrangements were found in 40 probands (16 TSC1, 24 TSC2) and nontruncating mutations in 8 (1 TSC1 and 7 TSC2). In five sporadic cases no mutation could be detected in either gene (TSC0).
Phenotype comparisons. The patients were first split up into three groups (table 1): 1) patients in whom no mutation was identified (TSC0), 2) patients with a TSC1 mutation, and 3) patients with a TSC2 mutation. Comparisons were limited to Numbers of patients in whom independent and dependent variables were obtained, separately shown for TSC1, TSC2, and TSC0
the TSC1 and TSC2 groups as the TSC0 group was too small for statistical analysis.
Gender and age at examination did not differ significantly between the TSC1 and TSC2 groups (table 1) .
Age at seizure onset was lower in the TSC2 mutation group (hazard ratio 2.2; 95% CI 1.2 to 4.2) and IS tended to be more common in patients with a TSC2 mutation (risk ratio 2.5; 95% CI 0.8 to 7.4). None of the other epilepsy variables was significantly associated with either the TSC1 or the TSC2 mutation group.
Group-wise, patients with a TSC2 mutation had a lower cognition index than patients with a TSC1 mutation (mean difference Ϫ0.7, 95% CI Ϫ1 to Ϫ0.2). The ranges of the cognition indexes in the TSC1 (range 1 to 3.7) and TSC2 (range 1 to 3.5) groups overlapped almost completely (table 1). The major contributor to the cognition index, IE, showed a clear bimodal distribution only in the TSC2 group (figure 2). Two patients with a TSC1 mutation had no history of seizures. One of these patients had an IE below 85 (1 SD below the mean). In the TSC2 group, four patients had no history of seizures; three of these had an IE lower than 85 and one patient had an IE below 70. There was no difference between the groups in the impact of epilepsy on the cognition index. Patients with a TSC2 mutation had more tubers (mean difference 9; 95% CI: 3 to 15; table 2) as well as a greater TBP (mean difference 1.1, 95% CI: 0.6 to 1.7) than patients with a TSC1 mutation, but ranges overlapped.
Comparisons of the 45 sporadic patients (including 18 with a confirmed de novo mutation and 5 without a mutation detected) with the 13 familial patients (12 confirmed) revealed a lower age at seizure onset (hazard ratio 2.3; 95% CI 1.1 to 4.8; table 2) and a lower cognition index (mean difference 1.0, 95% CI 0.5 to 1.5) in the group with sporadic TSC. Differences in tuber load between familial and sporadic patients were not found. Sporadic patients with a TSC2 mutation had more tubers (mean difference 10; 95% CI: 1 to 18) and a greater TBP (mean difference 1.1, 95% CI 0.3 to 2) than those with a sporadic TSC1 mutation (data not shown).
We compared patients with a GAPϪ mutation with those with a GAPϩ mutation once including and once excluding the TSC1 patients (table 3) . When patients with a TSC1 mutation were included, patients in the GAPϪ group tended to have a history of IS more often (risk ratio 2.1; 95% CI 0.9 to 5.1). Further, the GAPϪ group had more tubers (mean difference 6; 95% CI 0.3 to 12.2; table 2) and a greater TBP (mean difference 1.1; 95% CI 0.5 to 1.6) than the GAPϩ group. When we excluded all the patients with a TSC1 mutation from the analysis, we found that in the GAPϪ group secondary generalized tonic clonic seizures (sGTCS) (risk ratio 0.4; 95% CI 0.2 to 0.7; table 2) and multiple types of seizure (risk Table 1 Demographics and phenotype variables shown separately for TSC1, TSC2, and TSC0 *Here P ϭ no. of patients with below average cognition index. P ϭ no. of patients with the symptom; N ϭ no. of patients examined; IS ϭ infantile spasms; GTCS ϭ generalized tonic clonic seizures; CPS ϭ complex partial seizures; TS ϭ tonic seizures; TBP ϭ tuber/brain proportion.
ratio 0.4; 95% CI 0.2 to 0.6) were less common than in the GAPϩ group. When comparing patients with truncating mutations with those with nontruncating mutations (tables 2 and 4), we found that patients with truncating mutations were less likely to have had sGTCS (RR 0.4; 95% CI 0.2 to 0.7) and multiple types of seizure (RR 0.3; 95% CI 0.2 to 0.6) than patients with non-truncating mutations. With respect to the cognition index and tuber load no differences were identified.
DISCUSSION Several genotype-phenotype studies have reported that, as a group, TSC patients with a TSC2 mutation have a more severe phenotype than those with a TSC1 mutation. 3, [10] [11] [12] 17, 18 Our analysis is consistent with these findings. In our study, patients with a TSC2 mutation had an earlier age at seizure onset, a lower mean cognition index, more tubers, and a greater TBP than patients with a TSC1 mutation. However, the considerable overlap of the cognition indexes between the TSC1 and TSC2 groups (96%; the cognition index of only two patients from the TSC1 group exceeded the highest cognition index in the TSC2 group) means that in patients with a TSC2 mutation, cognitive impairments are more frequent but not necessarily more severe than in patients with a TSC1 mutation.
Sporadic TSC was associated with an earlier age at seizure onset and a lower cognition index than familial TSC. Within the sporadic group, only a more severe tuber load (more tubers and greater TBP) distinguished patients with a TSC2 mutation from patients with a TSC1 mutation.
We included five affected relatives (four parents, one sister) of probands in our patient sample. In four patients the diagnosis was confirmed by DNA analysis of the affected relative. In one patient no DNA was available for testing. The diagnosis in these five relatives was made after the proband presented with neurologic symptoms. Only one of them had epilepsy and none of them had a cognitive deficit, which may have contributed to the differences between familial and sporadic cases. However, we decided to include these individuals to maximize the size of our sample.
The overrepresentation of cognitive impairment in patients with a TSC2 mutation might be due to a higher frequency of somatic, inactivating mutations at the TSC2 locus. An alternative possibility is that patients with TSC1 mutations may still retain some rheb GAP activity since the tuberin GAP domain is still present. Patients from the GAPϪ group tended to have had a history of IS more often. Further, they had more tubers and a greater TBP than patients from the GAPϩ group. IS and a high TBP are associated with a lower cognition index.
14 Restricting the comparison to patients with a TSC2 mutation, we did not find any evidence for a greater TBP in the GAPϪ group compared with the GAPϩ group. Furthermore, IS were not more frequent in the TSC2 GAPϪ group than in the TSC2 GAPϩ group. Therefore, although the number of patients is very small, our data are consistent with a causal relationship between higher rates of somatic mutation at the TSC2 locus and more severe phenotypes in the TSC2 mutation group. Values in parentheses are 95% CIs. *Patients with a TSC2 mutation and epilepsy had a 2.2 higher risk of early epilepsy than those with a TSC1 mutation and epilepsy. †Cognition index was 0.7 lower in patients with a TSC2 mutation. ‡Patients with a TSC2 mutation had a higher number of tubers than those with a TSC1 mutation; mean difference of 9. §Patients with TSC2 mutations only. RR ϭ risk ratio; HR ϭ hazard ratio; GAP ϭ GTPase activating protein; GTCS ϭ generalized tonic clonic seizure; TBP ϭ tuber/brain proportion.
When comparing nontruncating with truncating mutations, the only significant differences between the groups were the higher prevalence of sGTCSs and multiple types of seizures in the group with nontruncating mutations. One possible explanation for this is that mutant hamartin and tuberin isoforms may have dominant negative effects on neuronal function. Further study is required to clarify this issue.
A relation between age at seizure onset, the presence of IS, and cognition has been reported extensively. [19] [20] [21] [22] [23] The assumption that patients without epilepsy have a normal cognitive function is not supported by our data. Four of the six patients without a history of seizures had significant cognitive impairment (IE more than 1 SD below the mean). Evidence for a bimodal distribution of estimated IQ in TSC (with a high frequency of IQ scores around 30 and a less conspicuous peak around 80) has been described previously. 19 We can now add that only the TSC2 group showed a bimodal distribution, with a peak around 50 rather than 30 (figure 2). Unfortunately, we were unable to determine how IQ scores below 50 were calculated, so differences between these data and ours may be due to different procedures for extrapolation.
To the best of our knowledge, the current study is the first to assess the relationships between mutation types, neurologic phenotype, and cognitive functioning on the basis of objective tuber load assessment and standardized measures of intelligence and other cognitive domains. The widely varying ages and cognitive abilities of the patients necessarily resulted in widely varying neuropsychological data sets. Transforming the Table 3 Phenotype variables shown separately for mutations deleting the tuberin GTPase activating protein (GAP) domain (GAPϪ) and mutations with retained GAP domain (GAPϩ) The entries refer to all patients and to patients with TSC2 only. *Here P ϭ no. of patients with below average cognition index. P ϭ no. of patients with the symptom; N ϭ no. of patients examined; IS ϭ infantile spasms; GTCS ϭ generalized tonic clonic seizure; CPS ϭ complex partial seizures; TS ϭ tonic seizures; TBP ϭ tuber/brain proportion. *Here P ϭ no. of patients with below average cognition index. P ϭ no. of patients with the symptom; N ϭ no. of patients examined; IS ϭ infantile spasms; GTCS ϭ generalized tonic clonic seizures; CPS ϭ complex partial seizures; TS ϭ tonic seizures; TBPϭ tuber/brain proportion.
different measures into a cognition index enabled us to process the data of all patients. A severely below average cognition index in 48% of the patients in our sample concurs with the incidence of mental retardation in the TSC population as reported in the literature. 2 A couple of methodologic objections can be raised. First, in our cohort there was a preponderance of children younger than 5 years (20%). However, as the age distribution was equal for both the TSC1 and TSC2 groups, and as only one of these younger children did not have seizures, we believe that the skewed age distribution did not bias our analysis. Second, this study was performed in a tertiary referral center where intractable epilepsy is a major field of interest. However, as the incidence of seizures in our sample (90%) is in agreement with the reported prevalence in TSC populations, selection bias is unlikely. In two patients we had to rely on historical data to outline the epilepsy syndrome, so an incidental misclassification is possible. We were unable to analyze the relation between genotype and phenotype in patients without epilepsy because only six such patients were included in our sample.
Because a strict relationship between mutation type and either seizures or the degree of cognitive impairment is lacking, these aspects of the disorder's severity are probably modified by other (genetic and nongenetic) factors. Whether variables within the phenotype, i.e., tuber load, are better predictors of epilepsy and cognition than the germ-line mutation is addressed in a companion paper.
Figure 2
Bar graph showing the distribution of intelligence equivalent (IE) in 17 patients with a TSC1 mutation (A) and in 31 patients with a TSC2 mutation (B)
